Clinical effect of recombinant human brain natriuretic peptide in the treatment of heart failure in elderly patients.
Humans
Heart Failure
/ drug therapy
Natriuretic Peptide, Brain
/ therapeutic use
Aged
Female
Male
Retrospective Studies
Recombinant Proteins
/ therapeutic use
Treatment Outcome
Recovery of Function
Ventricular Function, Left
/ drug effects
Aged, 80 and over
Biomarkers
/ blood
Age Factors
Time Factors
Cardiac function
Clinical efficacy
Recombinant human brain natriuretic peptide
Senile heart failure
Journal
BMC cardiovascular disorders
ISSN: 1471-2261
Titre abrégé: BMC Cardiovasc Disord
Pays: England
ID NLM: 100968539
Informations de publication
Date de publication:
27 Sep 2024
27 Sep 2024
Historique:
received:
16
04
2024
accepted:
12
09
2024
medline:
28
9
2024
pubmed:
28
9
2024
entrez:
28
9
2024
Statut:
epublish
Résumé
Heart failure in elderly individuals poses significant challenges due to the decline in cardiac function associated with aging. This study aimed to investigate the clinical efficacy of recombinant human brain natriuretic peptide (rhBNP) for the treatment of heart failure, especially in elderly patients. This was a retrospective case control study of the medical records of 60 elderly patients with heart failure admitted to our hospital between December 2020 and December 2023. Patients were divided into two groups based on treatment. The control group (n = 30) received diuretics, digitalis, and β receptor blockers, while the observation group (n = 30) received lyophilized rhBNP in addition to the control group treatment. Changes in BNP levels and clinical outcomes were compared between the two groups. Posttreatment BNP levels were significantly lower in the observation group than in the control group (p < 0.05), and the total clinical effective rate was greater in the observation group (p < 0.05). Additionally, the left ventricular diameter, left atrial diameter, left ventricular shortening fraction, diastolic flow signal and cardiac output in the observation group were lower than those in the control group (p < 0.05), while the thickness of the aortic root diameter in the observation group was greater than that in the control group (p < 0.05). RhBNP demonstrated ideal clinical efficacy in elderly patients with heart failure, improving symptoms and indicating potential for widespread use in the future.
Sections du résumé
BACKGROUND
BACKGROUND
Heart failure in elderly individuals poses significant challenges due to the decline in cardiac function associated with aging. This study aimed to investigate the clinical efficacy of recombinant human brain natriuretic peptide (rhBNP) for the treatment of heart failure, especially in elderly patients.
METHODS
METHODS
This was a retrospective case control study of the medical records of 60 elderly patients with heart failure admitted to our hospital between December 2020 and December 2023. Patients were divided into two groups based on treatment. The control group (n = 30) received diuretics, digitalis, and β receptor blockers, while the observation group (n = 30) received lyophilized rhBNP in addition to the control group treatment. Changes in BNP levels and clinical outcomes were compared between the two groups.
RESULTS
RESULTS
Posttreatment BNP levels were significantly lower in the observation group than in the control group (p < 0.05), and the total clinical effective rate was greater in the observation group (p < 0.05). Additionally, the left ventricular diameter, left atrial diameter, left ventricular shortening fraction, diastolic flow signal and cardiac output in the observation group were lower than those in the control group (p < 0.05), while the thickness of the aortic root diameter in the observation group was greater than that in the control group (p < 0.05).
CONCLUSION
CONCLUSIONS
RhBNP demonstrated ideal clinical efficacy in elderly patients with heart failure, improving symptoms and indicating potential for widespread use in the future.
Identifiants
pubmed: 39333886
doi: 10.1186/s12872-024-04190-6
pii: 10.1186/s12872-024-04190-6
doi:
Substances chimiques
Natriuretic Peptide, Brain
114471-18-0
Recombinant Proteins
0
Biomarkers
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
517Informations de copyright
© 2024. The Author(s).
Références
Callahan K, Kitko L, Van Scoy LJ, Hollenbeak CS. Do-not-resuscitate orders and readmission among elderly patients with heart failure in Pennsylvania: an observational study, 2011–2014. Heart Lung. 2020;49(6):812–6.
doi: 10.1016/j.hrtlng.2020.09.012
pubmed: 33010520
Deng H, Li Q, Zhu D. Therapeutic effects of allopurinol on the function of left ventricular and activity of matrix metalloproteinase enzymes (MMPs) in patients with chronic heart failure. Cell Mol Biol. 2022;68(5):96–102.
doi: 10.14715/cmb/2022.68.5.13
pubmed: 36029496
Mordi IF, Ouwerkerk W, Anker SD, et al. Heart failure treatment up-titration and outcome and age: an analysis of BIOSTAT-CHF. Eur J Heart Fail. 2021;23(3):436–44.
doi: 10.1002/ejhf.1799
pubmed: 32216000
Dimitropoulos S, Mystakidi VC, Oikonomou E, et al. Association of soluble suppression of tumorigenesis-2 (ST2) with endothelial function in patients with ischemic heart failure. Int J Mol Sci. 2020;21(24):9385.
doi: 10.3390/ijms21249385
pubmed: 33317161
pmcid: 7764062
Chinese Society of Cardiology, Chinese Medical Association, Chinese College of Cardiovascular Physician, et al. Chinese guidelines for the diagnosis and treatment of heart failure 2024. Chin J Cardiol. 2024;52(03):235–275.
Kubo I, Izawa KP, Kajisa N, et al. Factors delaying the progress of early rehabilitation of elderly Japanese patients with heart failure. Aging Clin Exp Res. 2020;32(3):399–406.
doi: 10.1007/s40520-019-01213-7
pubmed: 31076966
Butler J, Yang M, Sawhney B, et al. Treatment patterns and clinical outcomes among patients < 65 years with a worsening heart failure event. Eur J Heart Fail. 2021;23(8):1334–42.
doi: 10.1002/ejhf.2252
pubmed: 34053163
Hanon O, Belmin J, Benetos A, et al. Consensus of experts from the French Society of Geriatrics and Gerontology on the management of heart failure in very old subjects. Arch Cardiovasc Dis. 2021;114(3):246–59.
doi: 10.1016/j.acvd.2020.12.001
pubmed: 33455889
Fuchida A, Suzuki S, Motoki H, et al. Prognostic significance of diastolic blood pressure in patients with heart failure with preserved ejection fraction. Heart Vessels. 2021;36(8):1159–65.
doi: 10.1007/s00380-021-01788-0
pubmed: 33528797
Moreno-Gonzalez R, Formiga F, Mora Lujan JM, et al. Usefulness of systolic blood pressure combined with heart rate measured on admission to identify 1-year all-cause mortality risk in elderly patients firstly hospitalized due to acute heart failure. Aging Clin Exp Res. 2020;32(1):99–106.
doi: 10.1007/s40520-019-01153-2
pubmed: 30790241
Shi L, Zhang Y, Zhang J, et al. Application of blood pre-albumin and NT-pro BNP levels in evaluating prognosis of elderly chronic heart failure patients. Exp Ther Med. 2020;20(2 PtB):1337–42.
doi: 10.3892/etm.2020.8865
pubmed: 32742368
pmcid: 7388205
Sara Maldonado-Martín, Brubaker PH, Ozemek C, et al. Impact of β-blockers on heart rate and oxygen uptake during exercise and recovery in older patients with heart failure with preserved ejection fraction. J Cardiopulm Rehabil Prev. 2020;40(3):174–7.
doi: 10.1097/HCR.0000000000000459
pubmed: 31899703
pmcid: 7682249
Gaborit FS, Kistorp C, Kumler T, et al. Diagnostic utility of MR-proANP and NT-proBNP in elderly outpatients with a high risk of heart failure: the Copenhagen heart failure risk study. Biomarkers. 2020;25(1/8):248–59.
doi: 10.1080/1354750X.2020.1732466
pubmed: 32126847
Zhang M, Ma N, Zang T, et al. Clinical value of N-terminal pro-brain natriuretic peptide (NT-proBNP) levels in the diagnosis of heart failure in elderly population. Basic Clin Pharmacol Toxicol. 2021;128(S3):71–2.
Molnar AO, Petrcich W, Weir MA, et al. The association of beta-blocker use with mortality in elderly patients with congestive heart failure and advanced chronic kidney disease. Nephrol Dial Transpl. 2020;35(5):782–9.
doi: 10.1093/ndt/gfz167
Chen J, Gu S, Song Y, et al. The impact of cardiomotor rehabilitation on endothelial function in elderly patients with chronic heart failure. BMC Cardiovasc Disord. 2021;21(1):524–259.
doi: 10.1186/s12872-021-02327-5
pubmed: 34724901
pmcid: 8561974